Biologics Production Core
$251,610P01FY2013CANIH
Fred Hutchinson Cancer Research Center, Seattle WA
Investigators
Linked publications & trials
Paper 37939122Paper 34649272Paper 33082277Paper 32980545Paper 32243637Paper 31582553Paper 31481510Paper 30596402Paper 30454872Paper 30310789Paper 30262560Paper 28566329Paper 28428282Paper 28055107Paper 27432875Paper 27214069Paper 27197068Paper 26818003Paper 26576864Paper 26455717Paper 26348890Paper 26347113Paper 26338894Paper 26237500Paper 26133724Paper 26133610Paper 26018193Paper 25998714Paper 25993198Paper 25785845Paper 25628467Paper 25533035Paper 25460570Paper 25445025Paper 25395425Paper 25261237Paper 25236531Paper 25076159Paper 24858425Paper 24749780Paper 24749757Paper 24707941Paper 24578502Paper 24530971Paper 23871782Paper 23704203Paper 23556108Paper 23471305Paper 23456518Paper 23356514Paper 23073268Paper 22955187Paper 22687452Paper 22611160Paper 22298418Paper 22214546Paper 21976541Paper 21730271Paper 21613259Paper 21508413Paper 21488858Paper 20702781Paper 20597486Paper 20578815Paper 20423225Paper 20127945Paper 20019612Paper 19786617Paper 19779884Paper 19515724Paper 19332764Paper 19182204Paper 19124831Paper 19118002Paper 18854559Paper 18623377Paper 18586921Paper 18502830Paper 18454687Paper 18452065Paper 18413376Paper 18381107Paper 18070719Paper 17922043Paper 17917964Paper 17898567Paper 17312330Paper 17303693Paper 16585217Paper 16269863Paper 16254140Paper 15701869Paper 15665621Paper 14527031Paper 13129395Paper 12750161Paper 12728403Paper 11964278Paper 11722986Paper 11319588
Abstract
Core C is responsible for the production of clinical grade anfi-CD45 BCS antibody and anti CD20 1F5 antibody and their derivatization with DOTA and conjugation to streptavidin. These reagents will be produced, purified and vialed in the Biologies Production Facility of the Fred Hutchinson Cancer Research Center. In addition. Core C will be responsible for cGMP-compliant vialing of DOTA-biotin supplied in bulk form from a contract manufacturer (Macrocyclics, Inc.) Materials will be produced under current good manufactured practice (cGMP) conditions and Drug Master Files (DMFs) have been filed with the Food and Drug Administration (FDA).
View original record on NIH RePORTER →